Sugi Predict

Sugi Predict / Compounds / SCHEMBL6734073

SCHEMBL6734073

SCHEMBL6734073

COc1ccc(C(=O)c2c(Cc3ccc(Br)cc3)oc(C)c2C)cc1C1CCCC1

nearest known ligand 0.39

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ PTGDR2 Q9Y5Y4 4/20 0.39
▸ PTGDR Q13258 2/20 0.39
▸ ACHE P22303 2/20 0.37
▸ BCHE P06276 1/20 0.37
▸ SMPD1 P17405 1/20 0.36
▸ PTPN1 P18031 2/20 0.35
▸ ALDH1A1 P00352 3/20 0.35
▸ MAPT P10636 2/20 0.35
▸ KMT2A Q03164 2/20 0.34
▸ HPGD P15428 1/20 0.34
▸ MEN1 O00255 1/20 0.34
▸ ALOX12 P18054 1/20 0.34
▸ HDAC1 Q13547 1/20 0.33
▸ HDAC2 Q92769 1/20 0.33
▸ LMNA P02545 1/20 0.33
▸ POLB P06746 1/20 0.33
▸ GAA P10253 1/20 0.33
▸ SMN1; SMN2 Q16637 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6735058 0.90 PTPN1 (0.43) PTGDR2ACHEBCHEPTPN1KMT2A
SCHEMBL6740349 0.87 NUDT1 (0.37) PTGDR2PTGDRALDH1A1MAPTKMT2A
SCHEMBL6730813 0.85 CYP1A2 (0.37) PTGDR2PTGDRACHEBCHEALDH1A1
SCHEMBL6736716 0.81 PTGDR2 (0.39) PTGDR2PTGDRACHEBCHESMPD1
SCHEMBL6736467 0.81 PTPN1 (0.55) PTGDR2PTGDRPTPN1MAPTLMNA
SCHEMBL7083770 0.79 PTPN1 (0.45) PTGDR2PTGDRPTPN1MAPTLMNA
SCHEMBL6731410 0.77 PTPN1 (0.37) ACHEPTPN1ALDH1A1MAPTKMT2A
SCHEMBL6735264 0.77 PTPN1 (0.40) PTPN1
SCHEMBL6736222 0.73 PTPN1 (0.62) PTPN1
SCHEMBL6734060 0.72 NUDT1 (0.34) PTPN1ALDH1A1MAPTKMT2AHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6683107-B2 THERAPY OF METABOLISM DISORDERS WYETH 2004-01-27 — — US disclosed
US-20030073709-A1 Furans, benzofurans, and thiophenes useful in the treatment of insulin resistance and hyperglycemia WYETH 2003-04-17 — — US disclosed
US-6451845-B1 ANTIDIABETIC AGENTS WYETH 2002-09-17 — — US disclosed
US-20020035272-A1 Furans, benzofurans, and thiophenes useful in the treatment of insulin resistance and hyperglycemia AMERICAN HOME PRODUCTS CORPORATION 2002-03-21 — — US disclosed
US-6248764-B1 ANTIDIABETIC AGENT; HYPOGLYCEMIC AGENT AMERICAN HOME PRODUCTS CORPORATION 2001-06-19 — — US disclosed
US-6103708-A USEFUL IN TREATING METABOLIC DISORDERS RELATED TO INSULIN RESISTANCE OR HYPERGLYCEMIA AMERICAN HOME PRODUCTS CORPORATION (US) 2000-08-15 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030073709-A1 Furans, benzofurans, and thiophenes useful in the treatment of insulin resistance and hyperglycemia GPR119, INSR, FFAR3 PTGDR2 2507/4885PTGDR 1995/4885ACHE 4758/4885
US-20020035272-A1 Furans, benzofurans, and thiophenes useful in the treatment of insulin resistance and hyperglycemia INSR, GPR119, FFAR3 PTGDR2 2433/4885PTGDR 1960/4885ACHE 4647/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.